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Abstract 
Recently the use of synthetic cannabinoids (SCs) has increased around the world. As a result, the 
importance for accurate analysis of SCs in human biological matrices is evident and continues to be 
especially challenging due to their chemical structures being constantly modified. Many methods 
have been published recently for the analysis of SCs in human biological samples. This review 
provides an overview of the analytical methods used for the analysis of SCs and their metabolites in 
biological specimens with a special focus on chromatographic analysis and sample preparation. 
Liquid chromatography assay is the most commonly used for confirmation purposes of SCs and their 
metabolites in biological matrices. In blood and oral fluid, analysis of SCs must be very sensitive. In 
urine, SCs have extensive metabolism pathways; therefore the main target compounds are their 
hydroxyl and carboxyl metabolites, which is important to recognise when establishing clinical and 
forensic toxicology analytical methods.   
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Abbreviations  
AAls                            Aminoalkylindoles  
AAPCC                        American Association of Poison Control Centres  
AB-001                       Adamantan-1-yl(1-pentyl-1H-indol-3-yl)methanone 
AB-CHMINACA         N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide 
AB-FUBINACA           N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide 
AB-PINACA                N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide 
ADB-CHMINACA      (N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)-1H- indazole-3-carboxamide) 
ADB-FUBINACA        N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide 
ADBICA                      N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-carboxamine 
ADB-PINACA             N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1Hindazole-3-carboxamide 
AKB48                        N-(1-Adamantyl)-1-pentyl-1Hindazole-3-carboxamide 
AM-1220                   [1-[(1-Methylpiperidin-2-yl)methyl]-1H-indol-3-yl]-(naphthalen-1-yl)methanone 
AM-1248                   Adamantan-1-yl[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]methanone 
AM-1241                   (2-Iodo-5-nitrophenyl)-[1-(1-methylpiperidin-2-ylmethyl)-1Hindol-3-yl]methanone 
AM-2201                   [1-(5-Fluoropentyl)-1H-indol-3-yl]-1-naphthalenylmethanone 
AM-2233                   (2-Iodophenyl)[1-[(1-methyl-2-piperidinyl)methyl]-1H-indol-3-yl]-methanone 
AM-679                     (2-Iodophenyl)(1-pentyl-1H-indol-3-yl)methanone 
AM-694                     1-[(5-Fluoropentyl)-1H-indol-3-yl]-(2-iodophenyl)methanone 
APCI                           Atmospheric pressure chemical ionisation 
APICA                         N-(1-Adamantyl)-1-pentyl-1Hindole-3-carboxamide 
 
CI                                Chemical ionization 
CP47, 497                  (2-[(1R,3S)-3-Hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol)   
EI                                 Electron impact           
ELISA                          Enzyme-linked immunosorbent assay 
EMCDDA                European Monitoring Centre for Drugs and Drug Addiction’s 
ESI                               Electrospray ionization 
EWDTS                       European Workplace Drug Testing Society 
5F-AKB48                  N-(1-Adamantyl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide 
5F-PB-22                   1-(5-Fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid 
FID                             Flame ionization detector 
GC                              Gas chromatography 
GC/MS                      Gas chromatography/mass spectrometry 
HEIA                          Homogeneous enzyme immunoassay 
HU-210                     3-(1,10-Dimethylheptyl)- 6aR,7,10,10aR-tetrahydro-1-hydroxy-6,6-dimethyl-6Hdibenzo[b,d]pyran-9-
methanol 
JWH-015                  1-Naphthalenyl(2-methyl-1-propyl-1H-indol-3-yl)methanone 
JWH-018                  1-Naphthalenyl(1-pentyl-1H-indol-3-yl)methanone 
JWH-019                  1-Naphthalenyl(1-hexyl-1H-indol-3-yl)methanone 
JWH-020                  1-heptyl-1H-indol-3-yl-1-naphthalenyl-methanone 
JWH-073                  1-Naphthalenyl(1-butyl-1H-indol-3-yl)methanone 
JWH-081                  4-methoxynaphthalen- 1-yl- (1-pentylindol- 3-yl)methanone 
JWH-122                  4-methylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone 
JWH-200                  1-Naphthalenyl[1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl]methanone 
JWH-203                  2-(2-Chlorophenyl)-1-(1-pentyl-1Hindol-3-yl)ethanone 
JWH-210                  4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone 
JWH-250                  2-(2-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)ethanone 
JWH-251                  2-(2-Methylphenyl)-1-(1-pentyl-1Hindol-3-yl)ethanone 
JWH-307                  [5-(2-Fluorophenyl)-1-pentyl-1Hpyrrol-3-yl](naphthalene-1-yl)methanone 
JWH-387                  (4-bromo-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)-methanone 
JWH-398                  1-pentyl-3-(4-chloro-1-naphthoyl)indole 
JWH-412                  (4-fluoro-1-naphthalenyl)(1-pentyl-1H-indol-3-yl)-methanone 
LC                              Liquid chromatography 
LC/MS                      Liquid chromatography/mass spectrometry 
LC–MS/MS              Liquid chromatography/tandem mass spectrometry 
LC–HR/MS              Liquid chromatography–high resolution mass spectrometry 
LLE                            Liquid–liquid extraction 
LOD                          Limit of detection 
LOQ                          Limit of quantification 
MAM-2201             [1-(5-Fluoropentyl)-1H-indol-3-yl](4-methyl-1-naphthalenyl)methanone 
MRM                        Multiple reaction monitoring 
MS                           Mass spectrometry 
MS-MS                    Tandem mass spectrometry  
NPD                          Nitrogen phosphorus detector 
NPS                          New psychoactive substances 
PB-22                       1-Pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester 
QUCHIC                  Quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate 
RCS-4                      (4-Methoxyphenyl)(1-pentyl-1Hindol-3-yl)methanone 
RCS-8                      1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole 
SALLE                      Salting-out liquid–liquid extraction 
SAMHSA                Substance Abuse and Mental Health Services Administration 
SCs                          Synthetic cannabinoids  
SIM                         Selected ion monitoring 
SLE                          Supported liquid extraction 
SoHT                       Society of Hair Testing 
SPE                          Solid-phase extraction 
THC                         Tetrahydrocannabinol  
TOF/MS                  Time-of-flight/ mass spectrometry 
UR-144                    (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone 
WADA                     World Anti-Doping Agency 
WIN48, 098            (4-methoxyphenyl)-[2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]methanone 
WIN55 212-2          R-(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1 
naphthalenyl)methanone mesylate 
XLR-11                     [1-(5-Fluoropentyl)-1H-indol-3-yl](2,2,3,3- tetramethylcyclopropyl)methanone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Introduction    
From 2004, illicit drugs manufacturers began to increasingly produce herbal mixtures under a variety 
of brand names, e.g. “Spice” and “K2” [1]. It has been sold in European countries such as 
Switzerland, Austria and Germany since at least 2006 [2]. To produce these, chemical additives are 
sprayed onto dried plant materials to achieve psychoactive effects, and these products started being 
marketed throughout the world as safe and legal alternatives to cannabis [3]. Mixtures of these 
drugs commonly have labels such as ‘incense’, ‘not for human consumption’ or ‘for aromatherapy 
only’ to try to avoid regulatory oversight [4]. They also often come without declaration of 
ingredients and some may still come with ingredients list, however it does not contain the true 
contents because SCs are omitted from them [5]. They have been easy to buy for several years over 
the internet, or in gas stations or “head shops" [6]. 
It was not really until 2008 that these new products became popular, coinciding with the time that 
media in Germany claimed that they were a ‘legal’ alternative to marijuana but could not be 
detected by common drug-screening tests [7]. By the end of 2008, forensic researchers had detected 
several synthetic cannabinoids (SCs) in these herbal smoking mixtures [8]. The most commonly 
detected compounds in the first generation of “Spice” products were CP‐47,497 and the JWH- series 
[9], named after John William Huffman, a professor at Clemson University who first synthesised 
them in the laboratory during 1990s while studying human endocannabinoid receptor systems and 
their potential as therapeutic agents for scientific research [10]. Since then, the number and type of 
Spice products and new SCs have increased continuously.   
SCs are the largest drugs group monitored by the European Monitoring Centre for Drugs and Drug 
Addiction’s (EMCDDA) early drug warning system [11]. In 2013, 21,495 seizures of SCs were reported 
across Europe which represents 40 percent of the total number of seizures of new psychoactive 
substances (NPS) [11]. During 2014, a total of 101 NPS were notified for the first time through the 
organisation’s early warning system (EWS), and 30 of these compounds were SCs [11]. According to 
the American Association of Poison Control Centres (AAPCC), the number of calls related to SCs 
exposure sharp increased from 2096 calls in 2010 to 6968 in 2011, and decreased to 5230 in 2012, 
and dropped to 2668 in 2013; the trend of the exposures of SCs was increased again with 3,677 calls 
in 2014 [12]. Many SCs are now designated Schedule 1 Drugs under the US Controlled Substance Act 
and similar legislation has been put in place in many countries in a bid to stem the flow of them [13]. 
The World Anti-Doping Agency (WADA) has classified designer cannabimimetics as prohibited 
substances in sports [14].       
SCs may cause serious toxicity and impairment of health, and as such, the development of analytical 
methods for the detection of these compounds in different biological matrices is very important for 
clinical and forensic purposes. However, the detection of SCs and metabolites in biological 
specimens using common drug-screening tests is difficult because SCs are structurally different from 
delta-9 tetrahydrocannabinol (THC), the primary psychoactive compound of cannabis [15, 16]. The 
analytical method development of SCs in biological specimens is challenging for many reasons; lack 
of available reference materials, the low concentrations of SCs in the body due to high potency, and 
the similarities of the structures of various SCs that may cause interference. Recently, several 
reviews on the toxicity, pharmacology and detection methods of SCs have been published [17-19]. 
This review will focus on the chromatographic analysis and sample preparation techniques of SCs 
and their metabolites in biological specimens. 
2. Pharmacological and toxicological aspects of synthetic cannabinoids   
After the completion of THC synthesis in 1964 by Raphael Mechoulam [20] and the identified of 
cannabinoid receptors CB1 [21] and CB2 in 1980s [22], the interest in synthesising cannabinoids has 
increased to the yield of more than 100 substances. SCs contain a great variety of structurally 
dissimilar compounds and this makes the classification of SCs is quite complex. 
The classification of SCs, based on the chemical structures was published by Thakur et al. [23] and 
Howlett et al. [24] and includes classical cannabinoids (e.g. HU-210, AM-906, nabilone), nonclassical 
cannabinoids (e.g. CP47,497), eicosanoids (e.g. Methanandamide), aminoalkylindoles (AAls) and 
others (e.g. JWH-307, AKB48) (Figure 1). AAls can be categorised into sub-groups includes 
naphthoylindoles (e.g. JWH-018, JWH-073, JWH-200, JWH-122, JWH-210, JWH-398, AM-2201), 
phenylacetylindoles (e.g. JWH-250, JWH-203, JWH-251, RCS-8), benzoylindoles (e.g. AM-694, RCS-4), 
naphthylmethylindoles (e.g. JWH-184), naphthylmethylindenes, adamantoylindoles (e.g. AM-1284), 
cyclohexylphenols, and tetramethylcyclopropylindoles.      
These compounds have structural features that allow binding to CB1 or CB2 or to both of them in the 
brain [25] which results in the creation of cannabis-like effects (e.g. impaired sense of time, 
paranoia, sedation, hallucinations, anxiety and tachycardia) [26, 27]. In In vitro studies, it was found 
that some of SCs bind to cannabinoid receptors (mostly CB1) more avidly than THC as measured by 
the affinity constant Ki and the effect of this is to produce more severe intoxication [27, 28].  
Some users reported and/or showed additional unique effects from SCs such as agitation [27], 
hypokalaemia, hyperglycemia, seizures and emesis [29, 30], acute kidney injury [31], stroke [32], 
myocardial ischemia secondary [33] and myocardial infarction [34]. SCs have also been reported in 
association with deaths in several publications. Behonick et al. [35] reported four deaths following 
use of 5F-PB-22. One death related to use of AM-2201 has been reported by Patton et al. [36]. 
Recently, ADB-CHMINACA (N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(cyclohexylmethyl)-1H- 
indazole-3-carboxamide) has been reported in association with two deaths; one has been reported 
by the Hungarian National Focal Point [37] and the other one has been reported by Hasegawa et al. 
[38] that occurred in Japan.              
The usual mode of administration for the SCs is smoking via a conventional cannabis pipe, in 
cigarette papers or via a water pipe [3]. Teske et al. [39] reported the maximum concentration of SCs 
in serum was in the range of 10 ng/ml after smoking approximately 50 μg/kg of JWH-018, and then 
decreases rapidly to less than 10 % of original concentration within 3 hours. SCs are easily 
metabolised to hydroxyl or carboxyl derivatives of the N-alkyl side chain or aromatic ring [40, 41]. 
Saito et al. [42] reported the accumulation of some SCs such as MAM-2201 in the adipose tissue due 
to their high lipophilicity.  
Due to extensive metabolism, urine analysis requires identification of their probable metabolites. 
The metabolism studies of SCs are based on in vivo experiments [40, 43-53] or on in vitro 
experiments with human or rat liver microsomes [24, 41, 43, 44, 53-63]. Due to the speed of both 
the emergence and spread of SCs on the world market, the pharmacokinetics properties of some SCs 
have not been satisfactorily investigated.    
3. Sample preparation  
Sample analysis workflow should include a process of sample collection, transportation, preparation, 
analysis and report generation. Forensic laboratories should follow procedures and 
recommendations for the selection of the appropriate specimens and on how to be collected and 
tested that managed by guidelines, such as those of the Substance Abuse and Mental Health 
Services Administration (SAMHSA), European Workplace Drug Testing Society (EWDTS) or Royal 
College of Pathologists (UK) in order to minimize the risk of errors. During transporting and storage, 
it should be considered that loss of analyte from samples could adversely affect the quality of test 
results. For the analysis of SC and metabolites in serum, urine and oral fluid, samples should be 
refrigerated or frozen to minimise degradation. For example, PB-22 and 5-F-PB-22 was reported to 
degrade significantly due to the instability of the ester bond in the structures [54].    
Sample preparation is an essential stage of the analytical process to convert the biological specimen 
into a form that is suitable for analytical investigation. The extraction step is the main part of the 
procedure of sample preparation, and presents two major advantages for the analysis process [64]. 
Firstly, it removes interfering matrix compounds (such as proteins, salts and phospholipids) which 
reduces background noise. Secondly, it concentrates the target drugs, increasing sensitivity and 
achieving lower limits of detection. In liquid chromatography-tandem mass spectrometry (LC-
MS/MS), suitable sample preparation is important to reduce matrix effect, which is a change in the 
ionisation process of the drug due to endogenous matrix components. Matrix effects may alter the 
MS response of the target drug resulting in ion enhancement (gain in signal) or suppression (loss of 
signal) leading to effect on the precision, accuracy and robustness of the method.  
Simple dilution, protein precipitation, liquid-liquid extraction (LLE), solid phase extraction (SPE), 
supported liquid extraction (SLE) and salting-out LLE (SALLE) have been used for the extraction of 
SCs.   
3.1 Protein precipitation 
Protein precipitation has been found to be more useful when analysing protein rich matrices, such as 
whole blood, serum and plasma. Some authors have used protein precipitation for the extraction of 
SCs [36, 65]. An organic solvent is added to the specimen to reduce the solubility of the solute and 
precipitate the protein, and then it can be removed from the specimen by centrifugation or 
filtration. Protein precipitation is a rapid and simple extraction technique; however, it does not 
remove many of the matrix interferences. 
3.2 Liquid-liquid extraction 
LLE is applicable with most types of matrices. In SCs extraction, LLE is usually used because of their 
high hydrophobicity. It has been used for the extraction of SCs in the following matrices: blood  [35, 
66-72], serum [39, 73-76], plasma [77], urine [40, 41, 47, 49, 51, 59, 72, 78-83], oral fluid [84, 85] and 
hair [86-90]. It involves adding an immiscible organic solvent such as tert-butyl methyl ether [41, 82], 
chloroform [50] and diethyl ether [40, 52, 79] to the sample, and mixing, removing the organic 
solvent. The target compounds transfer from the sample layer to the organic layer. A sufficient 
amount of solvent should be used to capture all of the drugs from the original sample. The two 
phases are agitated by shaking the mixture, and then the organic phase is allowed to separate.  
LLE offers better clean up than protein precipitation and it also removes protein. In addition, it can 
be optimised for different compound classes. However, it requires an evaporation step to remove 
excess of solvents prior to analysis and can be difficult to automate.  
3.3 Solid phase extraction 
In more recent years, SPE has become more popular as an extraction technique in analysing illicit 
drugs. Extraction of SCs using SPE has been used in blood and serum [91], urine [92-96] and oral fluid 
[45, 97, 98]. Different types of SPE columns can be used depending on the cost, availability and the 
nature of the analytes of interest. The sample matrix is allowed to pass via the sorbent to waste, 
with the target analytes being retained. A series of washing steps are essential to remove matrix 
interferences, and then target analytes are eluted back off and collected in a clean vial.  
SPE is the only extraction type that will remove the endogenous compounds that cause technical 
problems such as co-elution which may cause matrix effects. Ionisation of the compound occurs at 
the interface of the LC-MS. The using of suitable sample preparation (e.g. SPE) and deuterated 
internal standards can reduce matrix effects. SPE also concentrates and cleans up the samples. 
However, Grigoryev et al. [99] reported nearly identical amounts of matrix elements for LLE and SPE 
in the extracts of SCs in urine samples. Rigdon et al. [100] reported SPE give better recovery of 
carboxylated metabolites of JWH-018 and JWH-073  in urine samples than LLE. The disadvantages of 
SPE are the cost and time of method development and extraction.  
4. Analytical methods  
Immunoassays (e.g. enzyme linked immunosorbent assays ‘ELISA’) and separation methods such as 
gas chromatography mass spectrometry (GC-MS), LS-MS/MS have been used for studying SCs and 
metabolites in biological samples.    
4.1 Immunoassay technique  
Immunoassay is a rapid technique used as an initial screening test to eliminate negative samples. 
Whilst quick, it has limitations, such as lower specificity. Moreover, cross-reactivity and false 
positives can occur, and as such, toxicologists recommend that all positive immunoassay findings 
must be retested and confirmed by chromatographic analysis. Immunoassay tests have been used 
for the screening of SCs in oral fluid [101] and their metabolites in urine samples [82, 93, 102-104].  
Different commercial kits have been available for detecting SCs and metabolites, including those 
made by Randox Toxicology, Neogen Corporation, Cayman Chemical, Immunalysis Corporation and 
National Medical Services [103]. The main limitation of immunoassay is the inability to cross-react 
with newer analogues of SC as they become more widely used. It is difficult for the manufactures to 
keep up within the rapidly changing analogues in use. Rodrigues et al. [101] evaluated an ELISA 
targeting JWH-200 in oral fluid. They reported that in oral fluid ELISA targeting JWH-200 had limited 
cross-reactivity to JWH-018, JWH-073, JWH-015, JWH- 022, AM2201, AM2232 and AM1220.  
4.2 Gas chromatography  
GC-MS is a commonly used separation technique for identification and quantitation of drugs of 
abuse in biological samples in most laboratories. However, GC-MS has some disadvantages such as 
high retention and limitation on the masses of the analytes. In addition, compounds which are 
thermally labile might decompose in the GC injection port. Many compounds with a polar functional 
group such as an amino or hydroxyl groups can also cause a polar interaction between the 
compound and the column stationary phase that leading to poor detection of the analyte. To 
overcome these problems, derivatisation step must be added onto the extraction method for these 
compounds. Derivatisation can change the functional groups and chemical properties of the 
molecule, making them less reactive with the stationary phase and more stable. Derivatisation is 
also used to increase sensitivity and specificity, improve peak shape, reduces tailing of polar 
compounds and rise volatilisation and ionization to promote chromatography. However, this adding 
step consumes more time and reagent which can be toxic. Moreover, it may introduce another 
source of possible error.  
In SCs analysis, it seems essential to include a derivatisation step prior to GC analysis to increase 
detectability and stability of compounds and help to improve analytical efficiency [105]. SCs are 
organic compounds containing active and polar functional groups, and are allowed to react with 
different types of derivatisation reagents. The following derivatisations have been used for SCs: 
trimethylsilylation [9, 46, 80, 99], methylation [80], acetylation [46, 99] or trifluoroacetylation [46, 
99]. Acetylation is preferred to routine analyses despite the slightly lower sensitivity because 
trifluoroacetylation can cause low thermal stability for JWH-018, JWH-073, JWH-250 and their 
metabolites [99]. MS detector is mostly carried out for SCs detection. Other types in use are nitrogen 
phosphorus detector (NPD) [4] which is suitable for most types of aminoalkylindoles, and flame 
ionization detector (FID) [106, 107].  
Electron impact (EI) and chemical ionization (CI) are the most common ionization techniques in GC-
MS. Most of EI fragments molecules at 70 electron volts (eV), producing several fragmentation of 
molecules and more than those acquired by LC–MS that can provide useful structural information. 
Mass spectra under EI conditions differ significantly from one SC to another due to the great variety 
of their chemical structures. The fragmentations of SCs can take place on both sides of the carbonyl 
group. The mass-spectral fragmentation pattern of SCs also involves formations of different 
immonium ions at m/z = 127 and 155 (naphthyl and naphthoyl moieties) or 144 (indole moiety).     
Indeed, SCs are not ideal compounds for GC-MS analysis because they are neutral to weakly acidic 
compounds and have high molecular weight. Some SCs are very difficult to analyse using GC-MS. For 
example, ester analogs (e.g. PB-22) decompose (or participates in the ester-exchange reactions) in 
the injection port. Another example is that cyclopropyl (e.g. UR-144) undergoes a thermal 
degradation (isomerization) mainly in GC column [108, 109]. This is indicated by shape of 
chromatographic peaks and variation of GC conditions. Therefore, appropriate strategies for the 
identification of the thermal degradation product of SCs (e.g. UR or XLR series) should be used 
during method development stage. Suitable derivatisation agent should be added to the extracted 
drug prior to analysis. The injection port temperature can be reduced to prevent injection port 
degradation. Generally, the sensitivity of GC-MS is low, which makes the determination of SCs in 
biological samples particularly blood more challenging.  
4.3 Liquid chromatography 
LC is the most popular technique for the analyses of different types of human matrices containing 
SCs and their metabolites. In SCs analysis, as with most LC-MS methods, methanol or acetonitrile are 
commonly used for the organic solvent of the mobile phase. Acetic acid, formic acid or their salts are 
mainly chosen as buffer additives to enhance the ionisation leading to increase the sensitivity. C18 
columns are mainly performed for the separation of SCs and their metabolites during LC.   
The combination of LC with mass spectrometry (MS) can yield a powerful analytical tool for 
identification purposes. It is clear that tandem mass spectrometry is the preferred instrument for 
the detection of SCs because they offer more information about chemical structures than acquired 
by single mass spectrometry.         
Electrospray ionisation (ESI) or atmospheric pressure chemical ionisation (APCI) are usually used for 
ionisation. The fragmentation of the parent drug and their metabolites is similar for ESI+collision and 
EI modes. However, the m/z of the fragments is different. 
It was found that most of SCs are affected by the matrix compounds found in the sample [69, 79], 
particularly when ESI is used [110] . It has been recommended that the most effective way to 
minimise ME is to use of isotope-labeled internal standards [111]. However, this is not always 
possible due to the rapid proliferation of SCs on the world market and absence of certified reference 
material. Another solution to minimise the ME is to choose suitable sample preparation procedure. 
Due to the different ionisation processes, APCI seems to be less susceptible to matrix effects than ESI 
[112]. However, it was found that the responses of SCs are lower using APCI than with ESI [73].  
ESI and APCI interfaces operate in positive and negative polarity. In SCs’ analysis, positive polarity is 
commonly performed. The negative ionisation mode has been used for HU-210, CP 47,497 and its 
homologue due to the absence of nitrogen in the chemical structures of these compounds in 
contrast to almost all other SCs [82].  
MS detection can be performed in full scan, product ion scan mode, selected ion monitoring (SIM) 
and multiple reaction monitoring (MRM). Full scan mode reduces sensitivity however, and this may 
cause false negative result for analytes in low concentrations. Fragment ions are observed using 
product ion mode method when the protonated molecular ion ([M+H]+) is utilized as the precursor 
ion. Two product ions of acceptable abundance should be determined to ensure that the correct 
compound and achieve good sensitivity. SIM and MRM modes elevate sensitivity however, it is 
important to have information about the compounds and fragmentation patterns. 
4.4 Analytical challenges and solutions    
The speed of the emergence of SCs has resulted in several analytical challenges for clinical and 
forensic laboratories. Reference material for use in positive identifications is not readily available. In 
blood and oral fluid, parent compounds are found at extremely low concentrations therefore 
methods for analysis of SCs in these matrices must be very sensitive. To the best of our knowledge, 
libraries of reference mass spectra were not commercially available to assist the identifications, 
especially for the most recent drugs. Similar or overlapped mass spectra of SCs are sometimes 
obtained by GC-MS due to their structural similarities and isomeric forms. The misidentification of 
these drugs might increase when using only the information from the mass spectra. The 
identification of new compounds in a biological material without knowledge about their structure is 
very difficult, even if analysing using LS-MS/MS.   
To overcome these emerging challenges, different strategies should be applied. Forensic 
communities must monitor the world drug market to ensure that clinical and forensic laboratories 
are keeping up with the illegal drug suppliers. When new compounds appear in the drug-user 
marketplace, toxicologists need to respond quickly and identify suitable biomarkers via in vitro 
studies to detect intake. Toxicologists need also to address the synthesis of reference standard for 
these new compounds.      
Analytical methods for the identification of SCs should be continuously updated, improved and 
revalidated to cover the new drug. Because SCs contain a variety of functional groups, the extraction 
of SCs requires a general procedure. Very limited data on cut-offs, detection windows or expected 
concentrations of SCs have been published. Therefore, LODs should be determined as low as 
analytically possible. Nowadays, laboratories have gained more experience with these drugs. 
Therefore, toxicologists should collect larger databases of searchable mass spectral library of many 
SCs and their metabolites and biomarkers that can indicate SC use.     
To overcome the misidentification of various SCs, which have similar chemical structures that can 
produce very similar fragmentation patterns or to identify new compounds in a biological material, 
High Resolution (HR) MS or TOFMS can be used to estimate the structure and screen of parent drugs 
and their metabolites of SCs in specimens. The development of non-targeted methods using HRMS 
technique facilitates the detection of known or unknown compounds at the time of analysis. It can 
distinguish between different substances with the similar nominal molecular mass. Unlike MS 
analysers, new HRMS technology enables the identification of analytes based on the exact molecular 
formula because it offers mass assignment with an accuracy of 0.001 atomic mass units (amu) [113]. 
This new technology allows for retrospective data inquiry after library updates. The main challenge 
of non-targeted LC-HRMS screening methods is to achieve sufficient selectivity to identify low 
concentrations of SC [19]. Several non-targeted methods using HRMS technique for screening of 
drugs of abuse including SCs in biological matrices were published [89, 94, 114, 115]. These methods 
are enabling forensic laboratories to obtain accurate data of MS and MS/MS without pre-selecting 
substances.     
5. Synthetic cannabinoids detection in biological specimens 
The identification and determination of SCs and their metabolites can be performed in the analysis 
of various body fluids, including blood, urine, hair and oral fluid. Seized products, such as herbal 
blends and powders, can also be tested for the presence of SCs. The choice of the kind of sample 
matrix is a critical component of forensic toxicology investigation. It depends on many factors such 
as the availability of specimens and the purpose of analysis. Figure 2 illustrates the number of 
publications for each biological matrix since 2010. A summary of the published methods for 
determination of SCs and their metabolites in blood/serum/plasma, urine, oral fluid and hair are 
summarised in Tables 1, 2, 3 and 4 respectively.   
5.1 Blood, serum and plasma 
Blood can offer unique advantages over other matrices. It can be used for the determination of 
recent drug use as in the case for identifying drivers under the influence of illicit drugs [70, 116]. It 
also can be used for the determination of the concentrations and ratios of parent drug and 
metabolite that could yield useful information relating to acute or chronic drug use. However, blood 
sampling requires the presence of medical staff for the collection and there being a risk of infection.  
Hermanns-Clausen et al. [27] studied the clinical and laboratory findings for 29 patients seeking 
emergency treatment after use of SCs between September 2008 and February 2011. They found in 
poisoning cases, the concentrations of CP-47,497-C8, JWH-018, JWH-073, JWH-250, JWH-122, JWH-
081, JWH-015, JWH-210 and AM 694 in serum were between 0.1 and 190 ng/mL. 
In fatal cases, the concentrations of SCs in blood were 0.1-199, 0.1-68.3, 12, 1.1-1.5, 12.4 and 6.05- 
10.6 ng/mL for JWH-018 [67], JWH-073 [67], AM-2201 [36], 5F-PB-22 [35], MAM-2201 [42], and 
ADB-CHMINACA [38], respectively. However, the lethal doses for many SCs are still unknown. The 
concentrations of SCs in blood are usually very low however, and as such, analytical methods for 
detection need to be very sensitive. Another difficulty in determining SCs in blood specimens is the 
window for detecting acute intake is short (hours–days) [39]. In the case of long-term use of SCs, the 
windows for detection can be longer due to the accumulation of its presence in fatty tissues [117].  
A qualitative method for the detection of 20 SCs in blood using LC-TOF/MS and automated SPE was 
developed by Guale et al. [91]. Covering a wider scope, a qualitative method for the detection of 46 
SC and 8 labelled analogs in serum utilizing LC-MS/MS and heated electrospray ionization (ESI) to 
enhance the sensitivity was developed by Huppertz et al.  [76]. LODs ranged from 0.1 ng/ml to 0.5 
ng/ml. 
Kneisel et al. [75] developed a quantified method for the determination of 30 SCs in serum using LC-
MS/MS following an alkaline LLE with n-hexane/ethyl acetate (90:10) mixture. Recoveries were in 
the range of between 94% and 111%. LOQs and LODs were 0.1 - 2.0 and 0.01 – 2.0 ng/mL 
respectively. 833 authentic serum specimens from forensic cases were analysed between August 
2011 and January 2012. 227 (27.2 %) were positive for at least one of the following SCs: AM-2201, 
JWH-018, JWH-073, JWH-307, JWH-210, JWH-203, JWH-200, JWH-122, JWH-081, JWH-019 and RCS-
4. JWH-210 was the most prevalent of SCs in positive samples (80 %), then JWH-122 (63 %) and AM-
2201 (29%).    
An LC-MS/MS method after LLE for the quantitation of JWH-018, JWH-073, JWH 200, JWH-250, JWH-
081, JWH-015, WIN 55,212-2 and methanandamide and the detection of JWH-020 and JWH-019 in 
serum was developed by Dresen et al. [73]. All analytes were stable in serum under storage 
conditions of −20 °C. However, degradation of JWH-018 and JWH-081 and the respective internal 
standard JWH-018-d11 in serum samples stored in the autosampler at 4 °C by more than 15 percent 
after 5 hours. They also observed a degradation of JWH-073, JWH-081 and methanandamide in 
serum samples kept at room temperature in polypropylene and glass tubes by more than 15 percent 
after 72 hours. 101 authentic serum samples from 80 subject provided by police authorities and 
therapy and forensic psychiatric centres were analysed. 57 samples (56.4%) of the samples were 
found positive for at least one SC. Methanandamide, WIN 55,212-2, JWH-200, JWH-020 and JWH-
019 were not detected in any samples.    
5.2 Urine 
Urine is the most widely used matrix for toxicological analysis in providing evidence of drug use and 
assessing drug exposure. It is the preferred specimen for many laboratories because the collection of 
urine samples is easy and non-invasive and the concentrations of analytes are often higher when 
compared with sample of blood or oral fluid. Moreover, the detection time in urine is longer than 
blood (days–weeks). The prevalence of positive results in urine specimen for some compounds is 
higher than those observed in blood because the detection windows are longer for urine samples. 
However, there are some disadvantages with using urine as a sample, and these include the 
possibility of adulteration or substitution, and it is not suitable for identifying drivers suspected of 
being under the influence of drugs as only gives evidence of past use.  
The parent compounds of SCs may not be detectable in urine; therefore it seems essential to focus 
on metabolites [41]. The metabolisms of some of SCs are still under investigation which also makes 
analysis from urine samples more complicated. Hydrolysis with acids [46, 80, 99] or enzymes [40, 50, 
51, 59, 118] is required in the procedure of urine sample preparation for SCs because it was found 
that the percentage of conjugated form excreted of the hydroxylated metabolites of JWH-018, JWH-
073 and JWH-250 is very high [46, 51, 119]. JWH-122 and its respective fluorinated analogue, MAM-
2201 produced common metabolites, N-4-hydroxylated, N-5-hydroxylated and carboxylated JWH-
122 metabolites. The key factor to prove JWH-122 or MAM-2201 abuse is the relative 
concentrations of JWH-122 N-4-OH M and JWH-122 N-5-OH M [120]. N-4-hydroxylated JWH-122 
metabolite is the predominant in JWH-122 metabolism, whereas N-5-hydroxylated JWH-122 
metabolite was the primary metabolite of MAM-2201 [120].      
The first publication to identify the JWH-018 urinary markers after the smoking of illicit herbal 
mixtures was by Sobolevsky et al. in 2010 [40]. Urine samples were collected from three intoxicated 
people taken into police custody. The parent compound JWH-018 was not detected whereas the 
phase-1 metabolites were identified after de-conjugation. The Authors suggested a low content of 
the metabolites phase-1 in urine.  
Another confirmation LC-MS/MS method was developed to detect 9 hydroxypentyl, carboxylated 
and hydroxyindole metabolites from 8 parent SCs [79]. Samples were treated by enzymatic 
hydrolysis and LLE. The method was applied to urine samples obtained from a volunteer who 
smoked a mixture blend.    
An LC-MS/MS method using SPE and enzymatic hydrolysis for simultaneous quantification of 37 SCs 
metabolites such as N-hydroxypentyl and carboxy metabolites in urine was developed by Jang et al. 
[121]. All SCs metabolites were stable in urine stored at 4 °C and −20 °C for 14 days, and after three 
freeze–thaw cycles. LODs were between 0.1 and 1 ng/ml, and extraction recoveries were 65-99%. 
Wohlfarth et al. [122] developed an LC-MS/MS method using a library search for qualitative 
detection of 9 SC and 20 metabolites in human urine. Protein precipitation and enzymatic hydrolysis 
have been used for sample preparation. LODs ranged from 0.5 to 10 ng/ml. Recoveries were in the 
range of between 53 and 95% and matrix effects were between 95 and 122%.       
An LC-MS/MS method using SLE+ extraction for the simultaneous quantification of 20 SCs and 21 
metabolites, and semi-quantification of 12 alkyl hydroxy metabolites in urine was developed by 
Scheidweiler et al. [123]. SLE is analogous to traditional LLE. SLE+ which is a product of SLE 
containing plates and/or columns provides inherently cleaner extracts than other extraction 
techniques and high analyte recoveries. The method was conducted in two MRM injections; one in 
negative for HU-210 ionized and CP 47,497 compounds and one in positive ESI Mode for all other 
analytes. LODs for the evaluated drugs ranged from 0.1 to 1 ng/ml. Matrix effects and extraction 
efficiencies were - 73 to 52% and 44 to 110%, respectively.       
Kronstrand et al. [114] compared the performance of an immunoassay screening for SCs with a new 
developed non-targeted qualitative LC-HR/MS confirmation method in urine. Enzymatic hydrolysis 
and SALLE have been used for sample preparation for LC-HR/MS method. They observed no cross-
reactivity with UR-144 metabolites but there was cross-reactivity with JWH-122 and MAM-2201 
metabolites for the immunoassay. They found the immunoassay performed well for SCs present in 
the urine samples tested. Due to the rapidly changing of SCs which may cause problems for 
immunoassays and for confirmation methods, the using of time-of-flight mass spectrometry is 
necessary for forensic laboratories as the new SC can be quickly included to the method and 
identified.     
5.3 Oral fluid 
Illegal drugs are readily detectible in oral fluid specimens. Oral fluid can be used as an alternative to 
blood for identifying drivers that are suspected of driving under the influence, and in place of urine 
samples when testing for drugs usage in the work place. It is easy and rapid to obtain and is less 
prone to adulteration [84]. In addition, oral fluid containing parent SCs make the sample a good 
choice for testing in cases where metabolite references may be lacking, or if the target metabolites 
are still unknown [101]. However, there are some disadvantages; the sample volume must be 
sufficient for the analysis, and this amount could be difficult to obtain from some SCs abuser. Losses 
of the sample’s volume can also occur without adequate devices for collecting the sample.     
Different collection devices have been used for oral fluid collection including DCD 5000 Dräger [84], 
Intercept [85] and QuantisalTM [97, 101, 124]. Kneisel et al. [84] studied the detection of 30 SCs using 
LLE and LC-MS/MS in oral fluid. The Dräger DCD 5000 device was used for oral fluid sample 
collection. The linearity and accuracy were acceptable for 28 of the 30 SCs covered by the method. 
LOQs were in the range from 0.15 to 3 ng/ml and LODs ranged from 0.015 to 0.9 ng/ml. 264 
authentic oral fluid samples were tested. 31 (12%) samples were found positive for at least one of 
the following SCs: JWH-018, JWH-250, JWH-203, JWH-122, JWH-081, JWH-019, JWH-307, JWH-210, 
AM-694, AM-2201, MAM-2201, and RCS-4. JWH-210 was identified in 31 samples, whereas JWH-
122, JWH-081 and JWH-018 were identified in 17, 8 and 7 samples respectively.   
Coulter et al. [97] developed a quantitative method for the detection of 6 SCs in oral fluid using SPE 
following LC-MS/MS with MRM in ESI+ and ESI- mode, and achieved 0.5 ng/ml LOQ. They observed a 
degradation for JWH-250 in oral fluid specimens kept at room temperature for one week by 25 
percent of the initial concentration, while with refrigerated samples, the loss was only 10 percent. 
They also observed some degradation for JWH-073 and JWH-018 when stored at room temperature 
for one week, while when refrigerated, samples were stable. HU-210, CP 47,497 and its C8 
homologue showed losses of 9 to 14 percent at both storage conditions over one week.       
5.4 Hair 
Hair was first described as an alternative specimen for drugs testing in the field of toxicology in 1979, 
when used to document long-term drug exposure. Hair testing provides long-term histories via 
segmental analysis, because hair offers a larger detection window when compared with all the other 
types of specimens (up to months) [125]. Another advantage of hair as a sample is low potential for 
donor manipulation. However, hair testing has its disadvantages too. Environmental contamination 
especially through smoking of drug, for example, can have an effect on hair analysis, leading to false-
positive result [126]. According to the Society of Hair Testing (SoHT), preparation of a hair sample 
should include a washing step in the procedure prior to analysis to remove the superficial or surface 
drug [127]. This allows for demonstrating that the drug being recovered by the extraction procedure 
is an internally consumed drug.    
Hutter et al. [128] developed a comprehensive quantitative method using LC-MS/MS for the 
determination of 22 SCs in hair. The hair specimen was washed with water, petroleum ether and 
acetone, and then dried, and cut into pieces. Finally, it was extracted with using LLE prior to analysis. 
LOQ was 0.5 pg/mg for all analytes, except JWH-398, which was 5 pg/mg.      
Another quantitative method using LLE for the detection of 23 SCs in hair was developed by 
Salomone et al. [88]. The hair specimen was washed with dichloromethane, and extracted with n-
hexan/ethyl acetate (90/10). An LC-MS/MS and SRM in ESI+ mode were used for analysis. LOQ were 
in a range of 0.7 and 4.3 pg/mg except for HU-210, at 80 pg/mg. In 344 authentic hair specimens 
obtained in 2011 from individuals with drug abuse histories and drivers with suspended licences, 
4.36% (N=15) of the specimens were positive for at least one SC. The most prevalent compounds in 
positive samples was JWH-073 (N=11) at concentrations ranging from 1.6 to 50.5 pg/mg. 
An LC-HR/MS screening method for the detection of 50 NPS including 8 SCs that had been reported 
by the National Early Warning System in Italy between 2009 and 2011 in hair was developed by 
Gottardo et al. [89]. For sample preparation, hair underwent NaOH digestion overnight and LLE prior 
to analysis. LOD was 10 pg/mg. The method was applied to 435 authentic hair specimens from 
individuals with suspended driving licences in year 2010. 8 were found positive for: JWH-018, JWH-
081, JWH-073, JWH-122, JWH-250, with concentrations rate 0.010 - 1.28 ng/mg.                  
6. Conclusion  
Due to the recurring threat of SCs to public health and their rapidly increasing usage worldwide, it is 
necessary to develop reliable analytical methods for their detection in different biological matrices. 
SCs are constantly being modified and rapidly becoming widely available; therefore laboratories 
should update their scope for detecting the most prevalent compounds at specific time.  
LLE and SPE are the most widely used sample clean up procedures for the detection of SCs and their 
metabolites in biological specimens. The separation techniques GC-MS, LC–MS/MS and LC-QTOF/MS 
are mainly used to detect and quantify SCs present in different biological specimens as well as in 
“Spice” or “K2” products. LC–MS/MS is more convenient for the detection of SC and metabolites 
because it provides better sensitivity. Matrix effects must be evaluated during method validation.    
Selection of the appropriate specimen is an important step in forensic toxicology. In blood and oral 
fluid samples, parent compounds are found at extremely low concentrations therefore methods for 
analysis of SCs in these matrices must be very sensitive. Urine is the most commonly collected 
sample for monitoring recent exposure. However, the analysis of drugs in urine is complex because it 
requires knowledge and understanding of the drug’s metabolites. Hydrolysis with acids or enzymes 
should be performed in urine sample to enhance the sensitivity of detection. Blood and urine are the 
first choice of sample for SCs testing. Hair is often used as alternative sample in documenting drug 
exposure. Due to the stability issue of SCs, it is recommended to keep samples frozen whenever 
possible and sample extracts should be analysed shortly after extraction. We recommend that it is 
necessary to use HRMS to look for unknowns or keep updating your targeted method to 
include relevant analytes.  
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 Figure 2: Methods in different biological specimens for SC detection published between 2010 and 
2015. 
 
Table 1: Bioanalytical procedures for determination of SCs and metabolites in blood/serum/plasma samples. 
SCs Matrix Sample preparation Detection mode LOD (ng/mL) ; LOQ (ng/mL) References 
(25 SCs): JWH-018, JWH-073, JWH-081, JWH-203, JWH-210, JWH-250, 
JWH-251, JWH-007, JWH-015, JWH-019, JWH-030, JWH-302, JWH-398, 
CP47, 497, CP47, 497 C8-homolog, HU-210, AM-694, AM-1241, RCS-4, 
RCS-4 2- and 3-methoxy homolog, RCS-8, RCS-4-C-4-homolog, WIN48 
098, WIN55 212-2 mesylate  
Whole blood LLE LC-MS/MS-ESI+/- LOQ = 0.5 and 5 [66] 
(29 SCs): JWH-018, JWH-019, JWH-020, JWH-073, JWH-122, JWH-147, 
JWH-200, JWH-210, JWH-250, JWH-251, JWH-398, JWH-007, JWH-203, 
JWH-015, JWH-073-methyl, JWH-081, JWH-098, AM-1220, AM-1241, 
AM-2201, AM-2233, MAM-2201, AB-001, AM-694, RCS-4, RCS-4 ortho, 
RCS-8, UR-144, WIN55 212-2  
Whole blood LLE LC-MS/MS-ESI+ Not specified [68]  
(2 SCs): JWH-018, JWH-073 Whole blood LLE LC-MS/MS-ESI+ 0.01 ; 0.05  [67] 
(4 SCs): JWH-018, JWH-073, JWH-019, JWH-250 Whole blood LLE LC-MS/MS-ESI+ 0.006 ; 0.016 [69] 
(20 SCs and 7 metabolites):  AM-2201, AM-2201-N-4-OH-pentyl, JWH-
018, JWH-210, JWH-203, JWH-250, JWH-251, JWH-081, JWH-122, JWH-
122-N-5-OHpentyl, JWH-018-N-4- and 5-OH-pentyl, JWH-147, JWH-
200,JWH-200-4-OHindole, JWH-201, JWH-302, JWH-398, JWH-412, 
MAM-2201, RCS-4, RCS-4 ortho isomer, RCS-4-N-5- OH-pentyl, RCS-4- 
N-COOH, RCS-8, WIN48 098, WIN55 212 
Whole blood 
 
Protein precipitation 
 
LC-MS/MS-ESI+ Not specified  [36]  
 
(18 SCs): 5F-PB-22, JWH-018, JWH-073, JWH-019, JWH-122, JWH-210, 
JWH-250, JWH-015, JWH-081, AM-2201, Cl-2201, MAM-2201, UR-144, 
XLR-11, BB-22, PB-22, AB-PINACA, ADB-PINACA, 
Whole blood LLE LC-MS/MS Not specified [35] 
(13 SCs): JWH-018, JWH-073, JWH-081, JWH-019, JWH-122, JWH-200, 
JWH-210, JWH-250, JWH-175, AM-2201, AM-694, RCS-4, RCS-8  
Whole blood LLE LC-MS/MS-ESI+ Not specified  [70] 
 
(18 SCs): JWH-018, JWH-073, JWH-081, JWH-250, JWH-251, JWH-122, 
JWH-200, JWH-210, JWH-015, JWH-019, JWH-020, CP47, 497, HU-210, 
AM-694, AM-2201, RCS-4, RCS-4-C4, RCS-8, WIN55,212-2  
Whole blood LLE LC-MS/MS-ESI+ Not specified [71] 
UR-144 and pyrolysis product [1- (1-pentyl-1H-indol-3-yl)-3-methyl-2- 
(propan-2yl)but-3-en-1-one] 
Whole Blood LLE LC-MS/MS-ESI+ 0.15 ; 0.5  [72] 
(10 SCs): JWH-018, JWH-073, JWH-081, JWH-250, JWH-015, JWH-200, 
JWH-019, JWH-020, WIN55 212-2, methanandamide 
Serum LLE LC-MS/MS-ESI 0.1 ; 0.1 - 0.6  [73]  
 
(15 SCs): JWH-018, JWH-073, JWH-081, JWH-019, JWH-122, JWH-200, 
JWH-210, JWH-250, JWH-251, JWH-203, JWH-307, JWH-015, AM-1220, 
AM-2201, AM-694  
Serum LLE LC-MS/MS-ESI+/- 0.02 - 0.4 ; 0.05 - 0.5 [74] 
JWH-018 Serum LLE LC-MS/MS-ESI+ 0.07 ; 0.21  [39] 
(2 SCs): PB-22 and UR-144 Serum Not specified LC-TOF-MS Not specified [129]  
(30 SCs): JWH-018, JWH-018 adamantyl derivative, JWH-073, JWH-081, 
JWH-122, JWH-122 5-fluoropentyl derivative, JWH-200, JWH-210, JWH-
250, JWH-251, JWH-015, JWH-019, JWH-020, JWH-203, JWH-307, JWH-
387, JWH-398, JWH-007, AM-694, AM-1220, AM-2201, AM-2233, MAM-
2201, methanandamide, CRA-13, RCS-4, RCS-4 ortho isomer, RCS-8, 
WIN 48 098, WIN 55 212-2 
Serum LLE LC-MS/MS-ESI+ 0.01 - 2.0 ; 0.1 - 2.0  [75] 
 
(46 SCs): JWH-018, JWH-073, JWH-081, JWH-122, JWH-182, JWH-200, 
JWH-007, JWH-015, JWH-019, JWH-210, JWH-250, JWH-251, JWH-020, 
JWH-022, JWH-203, JWH-307, JWH-370, JWH-387, JWH-398, JWH-412, 
AM-694, AM-1220, AM-1220 azepane isomer, AM-2201, APICA, AM-
1248, AM-2232, AM-2233, MAM-2201, Methanandamide, AB-001, 
Cannabipiperidie- thanone, CRA-13, RCS-4, RCS-4-C4, RCS-4 ortho 
isomer, RCS-8, STS-135, UR- 144, UR-144 isomer, XLR-11, XLR-11 
isomer, WIN48 098, WIN55 212-2, AKB48, 5F-AKB-48 
Serum LLE LC-TOF/MS-ESI+ LOD = 0.1 - 0.5  [76] 
 
(5 SCs): JWH-122, PB-22, AM-2233, BB-22, 5F-PB-22  Plasma LLE LC-HR-MS Not specified [77] 
(20 SCs): JWH-018, JWH-073, JWH-081, JWH-122, JWH-200, JWH-007, 
JWH-015, JWH-016, JWH-018-6-MeO, JWH-098, JWH-210, JWH-250, 
JWH-022, JWH-203, AM-694, AM-2201, AM-1241, RCS-4, RCS-8, WIN 48 
098  
Blood, serum SPE LC-TOF/MS-ESI+ Not specified [91] 
 
 
 
 
 
 
 
 
 
 
 Table 2: Bioanalytical procedures for determination of SCs and metabolites in urine samples. 
SCs Sample preparation Detection mode LOD (ng/mL) ; LOQ (ng/mL) References 
(5 metabolites of JWH-018): JWH-018 N-5-OH-pentyl, 5-OHindole, N-COOH, N-dealkylated-5-
OH-indole and 2-OH-naphthoyl  
Hydrolysis, LLE LC-MS/MS-ESI+ 0.1 ; 0.5 (Only for JWH-018-
N-OH-pentyl and N-COOH) 
 [49] 
 
Metabolites of JWH-018 and AM-2201 Hydrolysis, LLE LC-HR/MS Not specified [78]  
(3 metabolites of JWH-018): N-5-OH-pentyl, N-COOH, 6-OH-indole Hydrolysis, LLE LC-MS/MS-ESI+ 0.01 - 0.1 ; 1 [50] 
(10 metabolites of 7 SCs): JWH-018 N-5-OH-pentyl, -COOH, JWH-073 N-4-OH-butyl, -COOH, 
JWH-250 5-OH-indole, N-COOH, JWH-122 N-5-OH-pentyl, JWH-200 5-OH-indole, JWH-019 5-
OH-indole, RCS-4 N-5- OH-pentyl 
Hydrolysis, LLE LC-MS/MS-ESI+ LOQ = 0.1  [79] 
 
JWH-018 and its metabolites  Hydrolysis, LLE LC-MS/MS heated- 
ESI 
Not specified  [40] 
(JWH-018 and 7 metabolites): JWH-018 N-5-OH-pentyl, N-COOH, 2-, 4-,5-,6- and -7-OH-
indole 
(JWH-073 and 6 metabolites): JWH-073 N-4-OHbutyl, N-COOH, 4-, 5-, 6- and -7-OH-indole 
LLE/SPE LC-MS/MS-ESI+ LOD = 1  [92]  
 
Metabolites of UR-144 Hydrolysis GC-MS, LC-MS/MS Not specified [109]  
CP47, 497 Dilution LC-MS/MS-ESI- 10 ; 20  [130] 
(JWH-018 and 6 metabolites): JWH-018 N-5-OH-pentyl, –COOH and 4-, 5-, 6-, 7-OH-indole 
(JWH-073 and 6 metabolites): JWH-073 N-4-OH-butyl, -COOH and 4-,5-,6-,7-OH-indole 
Hydrolysis, LLE LC-MS/MS-ESI+ < 2 ; 1.8- 10.8 [51] 
 
(3 metabolites of JWH-018): JWH-018 N-4- and 5-OH-pentyl and COOH 
(3 metabolites of JWH-073): JWH-073 N-3- and 4-OH-butyl and COOH. 
Hydrolysis, SPE LC-MS/MS-ESI+ 0.1 ; 0.1 [119] 
 
JWH-018 and 19 metabolites (mainly hydroxylated and N-dealkylatedmetabolites) Hydrolysis, LLE LC-MS/MS-ESI+ LOD = 0.1  [59] 
AB-001 and 7 metabolites Hydrolysis, LLE GC-MS Not specified [80]  
(4 metabolites of JWH-018): JWH-018 N-COOH,  6-OH-indole,  N-4- and 5 OH-pentyl 
(4 metabolites of JWH-073):  JWH-073 N-COOH, 6-OH-indole,  N-3- and 4-OH-butyl  
Dilution, Hydrolysis, 
SPE 
ELISA, LC-
MS/MSESI+ 
0.025 – 0.1 ; 2.5  [93] 
(UR-144 and 5 metabolites): despentyl-OH-UR-144, di- OH-UR-144, despentyl-UR-144, 
dehydrated OH-UR-144, OH-UR-144 
(AM2201 and 7 metabolites): JWH-018 N-(5-OH-pentyl), N-(5-OH-pentyl) dihydrodiol-JWH-
018, di-OH-AM-2201, dihydrodiol-AM-2201, OH-AM-2201,despentyl-AM-2201, JWH-018 N-
COOH 
Hydrolysis, LLE LC-MS/MS-ESI+ Not specified [47] 
 
RCS-4 and its metabolites Hydrolysis, LLE, GC-MS Not specified [81] 
(8 metabolites of 5 SCs): JWH-018 N-4- and 5-OH-pentyl, JWH-073 N-3- and 4-OH-butyl, 
JWH-250 N-4-OHpentyl, JWH-019 N-5- and 6-OH-hexyl, AM-2201 N-4-OH-pentyl  
Hydrolysis, LLE ELISA, LC-MS/MS-
ESI+ 
Not specified [82]  
 
5-F-AKB48 and its metabolites Hydrolysis, LLE LC-HRAM-MS Not specified [131] 
(37 metabolites of 17 SCs): JWH-018 N-COOH, -6-OH-indole, N-4- and 5 OH-pentyl, JWH-073 
N-COOH, 6-OH-indole,  N-3- and 4-OH-butyl, JWH-250 N-COOH,  N-4- and 5 OH-pentyl,  JWH-
122 N-4- and 5 OH-pentyl, JWH-019 N-6 OH-pentyl, JWH-210 N-4- and 5 OH-pentyl, JWH-081 
N-5 OH-pentyl , JWH-398 N-4- and 5 OH-pentyl, JWH-203 N-COOH,  N-4- and 5 OH-pentyl, 
AM-2201-6-OH-indole, N-4 OH-pentyl, MAM-2201 N-COOH, N-4 OH-pentyl, UR-144 N-COOH,  
N-4- and 5 OH-pentyl, XLR-11 N-4 OH-pentyl, AB-PINACA N-COOH, N-4 OH-pentyl, 5F-AB-
PINACA N-4 OH-pentyl, AKB48 N-COOH,  N-4- and 5 OH-pentyl, 5F-AKB48 N-4 OH-pentyl      
Hydrolysis, SPE LC-MS/MS-ESI+  LOD = 0.1 - 1 [121] 
Major metabolites of JWH-018, JWH-073, JWH-081, JWH-122, JWH-210, JWH-250, RCS-4 Hydrolysis, LLE LC-MS/MS-ESI+, 
LC-TOF/MS-ESI+ 
Not specified  [41] 
(2 metabolites of JWH-018): JWH-018 N-4-OH-pentyl, N-COOH, 
(2 metabolites of JWH-073): JWH-073 N-3-OH-butyl, N-COOH  
Hydrolysis, LLE LC-MS/MS-ESI+ LOQ = 4 [83] 
(4 metabolites of JWH-018): JWH-018 N-4- and 5- OH-pentyl, N-COOH, methyl ester 
(2 metabolites of JWH-073): JWH-073 N-3-OH-butyl, N-COOH 
JWH-072 N-COOH  
Hydrolysis 
 
LC-MS/MS-ESI+ LOQ = 4 [132] 
(47 metabolites of 21 SCs): JWH-018 N-OH-pentyl, N-COOH, 5- and 6-OH-indole, JWH-073 N-
OH-butyl, 5- and 6-OH-indole, NCOOH, JWH-122 N-OHpentyl, N-COOH, JWH-250 5-OH-
indole, N-OH-pentyl, N-COOH, JWH-210 N-COOH, N-OH-pentyl, JWH-200 5- and 6-OH-indole, 
JWH-398 N-OH-pentyl, N-COOH, JWH-019 5-OH-indole, -OH-hexyl, JWH-081 N OH-pentyl, 
AM-2201 6-OH-indole, N-OH-pentyl, MAM-2201 N-OH-pentyl, RCS-4 N-OH-pentyl, N-COOH,  
M9, UR-144 N-OH-pentyl, N-COOH, degradant-COOH, XLR-11 N-OH-pentyl, 6-OH-indole, 
ADB-PINACA N-OH-pentyl, AKB48 N-OH-pentyl, N-COOH, 5F-AKB48 N-OH-pentyl, 5F-AB-
PINACA N-OH-pentyl, AB-PINACA N-OH-pentyl, -COOH, PB-22 N-OH-pentyl, N-COOH, N-OH-
pentyl-3-COOH-indole, N-COOH-3-COOHindole, 3-COOH-indole, 5F-PB-22 3-COOH indole 
Dilution, Hydrolysis, 
SLE+ 
LC-TOF/MS-ESI+ LOD = 0.25 - 20 [115] 
(35 SCs and 19 metabolites): JWH-018, JWH-018 N-4- and 5-OH-pentyl, N-COOH, -4-, 5-, 6- 
and 7-OH-indole, 6-methoxy-indole, -1-methyl-hexyl, JWH-073, JWH-073 N-3- and 4-OH-
butyl, -4-, 5-, 6-, and 7-OH-indole, N-COOH, 2- and 3-methyl homology, JWH-122, JWH-122 N-
5-OH-pentyl, JWH-200, JWH-200 4-OH-indole, JWH-250, JWH-251, JWH-081, JWH-147, JWH-
007, JWH-015, JWH-019, JWH-201, JWH-210, JWH-203, JWH-302, JWH-398, JWH-412, CP47, 
497,CP47, 497-C8, CP55,940, HU-210, AM-694, AM-1220, AM-1220 azepane isomer, AM-
2201, MAM-2201, RCS-4, RCS-4 ortho isomer,  N-5-OH-pentyl,  N-COOH, RCS-8, AB-0101, 
WIN48 098, WIN55 212 
Hydrolysis, SPE LC-TOF-MS-ESI+ Not specified       [94] 
 
22 SC and 37 metabolites No sample 
preparation 
Biochip array techn- 
ology immunoassay 
Not specified       [133] 
(9 SC and 20 metabolites):  JWH-018, JWH-018 N-5-OH-pentyl, 5- and 6-OH-indole, N-COOH, 
JWH-073, JWH-073 N-4-OH-butyl, N-COOH, 5- and 6-OH-indole, JWH-250 N-4- and 5-OH-
pentyl, 5-OH-indole, JWH-200 5- and 6-OH-indole, JWH-081, JWH-081 N-5-OH-pentyl, JWH-
210, JWH-210 N-4- and 5-OH-pentyl, N-COOH, JWH-122, JWH-122 N-5-OH-pentyl, AM-2201, 
AM-2201 6-OH-indole, N-4-OH-pentyl, MAM2201, RCS-4, RCS-4 N-5-OH-pentyl, N-COOH 
Protein precipitation, 
Hydrolysis 
LC-MS/MS-ESI+ LOD = 0.5 - 10 [122] 
 
JWH-018 N-COOH (calibrator) No sample ELISA Not specified       [103]  
preparation  
 (5 SC and 6 metabolites): JWH-018, JWH-018 N-4- and 5-OHpentyl, 4- and 5-OH-indole, 
JWH-073, JWH-073 N-3- and 4-OH-butyl, JWH-250, HU-210, AM-2201 
Hydrolysis, SPE LC-MS/MS-ESI+ 0.01 - 0.5 ; 0.05 - 5       [95]  
 
(20 SC and 33 metabolites): JWH-018, JWH-018 N-OH-pentyl, N-COOH, 5- and 6-OH-indole, 
JWH-073, JWH-073 N- OH-butyl, N-COOH, 5- and 6-OH-indole, JWH-019, JWH-019 5-OH-
indole, -N-OH-hexyl, JWH-250 N-OH-pentyl, N-COOH, -5-OH-indole, JWH-081, JWH-081 N-
OH-pentyl, JWH-210, JWH-210 N-OH-pentyl, N-COOH, 5-OH-indole, JWH-200 5- and 6-OH-
indole, JWH-122, JWH-122 N-OH-pentyl, JWH-398, JWH-398 N-OH-pentyl, N-COOH, JWH-
203, CP47, 497-C7, CP47, 497-C7-OH, CP47, 497-C8, CP47, 497-C8-OH dimethyloctyl, HU-210, 
AM-694, AM-2201, AM-2201 6-OH-indole, N-OH-pentyl, MAM-2201, MAM-2201 N-OH-
pentyl, N-COOH, UR-144 N-OH-pentyl, N-COOH, RCS-4, RCS-4 N-OH-pentyl, M9, M10, N-
COOH,  
Dilution, Hydrolysis, 
SLE 
LC-MS/MS-ESI+/- 0.05 - 1 ; 0.1 - 1        [123] 
 
(38 metabolites of 12 SCs): JWH-018 N-4- and 5-OH-pentyl, N-COOH, 5-, 6- and 7-OH-indole, 
JWH-073 N-3- and 4-OH-butyl, N-COOH, 5-, 6- and 7-OH-indole, JWH-250 N-4- and 5-OH-
pentyl, N-COOH, JWH-019 N-5- and 6-OH-hexyl, JWH-210 N-4- and 5-OH-pentyl, N-COOH, 
JWH-122 N-4-OH-pentyl, N-5-OH-pentyl, JWH-081 N-5-OH-pentyl, N-COOH, JWH-398 N-4- 
and 5-OH-pentyl, N-COOH, AM-2201 N-4-OHpentyl, 6- and 7-OH-indole, MAM-2201 N-4-
OHpentyl, N-COOH, UR-144 4- and 5-OH-pentyl, N-COOH, RCS-4 4- and 5-OH-pentyl, N-COOH 
SALLE HEIA, 
 LC-TOF/MS-ESI+ 
Not specified [114] 
 
(8 metabolites of 3 SCs): JWH-018 N-4 and 5-OH-pentyl, N-COOH, N-5-OH-pentyl  β-Gluc, 6-
OH-indole, JWH-073 N-COOH, AM-2201 N-4-OH-pentyl, 6-OH-indole  
Hydrolysis, SPE LC-MS/MS-ESI+ 0.1 ; 2.5 [96]  
(14 SC and 15 metabolites):  JWH-018 N-4-OH-pentyl, N-COOH, JWH-073 N-3-OH-butyl, -N-
COOH, JWH-250 N-4-OH-pentyl, JWH-122, JWH-122 N-5-OH-pentyl, JWH-081, JWH-081 N-5-
OH-pentyl, JWH-120, JWH-210 N-4-OH-pentyl, JWH-019, JWH-019 N-5-OH-hexyl, JWH-200 6-
OH-indole, HU-210, AM-694 N-COOH, AM-1248, AM-2201, AM-2201 N-4-OHpentyl, UR-144, 
UR-144 N-COOH, XLR-11, XLR-11 6-OH-indole, XLR-12, RCS-4, RCS-4 N-5-OH-pentyl, RCS-8, 
AB-FUBINACA, PB-22 
Hydrolysis, Dilution LC-MS/MS-ESI+ LOD/LOQ = 1 - 5 [134] 
(UR-144 and 7 metabolites): UR-144 N-COOH, di-OH-UR-144, UR-144 N-5-OH-pentyl- β-Gluc, 
despentyl-UR-144, despentyl-OH-UR-144, dehydrated-OH-UR-144, OH-UR-144 
Hydrolysis, LLE LC-TOF-MS-ESI+ 0.15 ; 0.5 [72] 
Table 3: Bioanalytical procedures for determination of SCs and metabolites in oral fluid samples. 
SCs Sample preparation Detection mode LOD (ng/mL); LOQ (ng/mL) References 
(10 SCs): JWH-018, JWH-073, JWH-250, JWH-122, JWH-019, JWH-200, HU-210, CP47,497, 
nabilone, AM-694 
Dilution LC-MS/MS-ESI+ LOD = 1 - 20 [135] 
(10 SCs): JWH-018, JWH-073, JWH-250, JWH-200, JWH-081, HU-210, CP47,497, CP47,497 (C8), 
AM-2201, RCS-4 
Dilution ELISA, LC-MS/MS-ESI+  0.1 ; 0.25 [101] 
(28 SCs): JWH-018, JWH-073, JWH-250, JWH-200, JWH-122, JWH-019, JWH-210, JWH-007, 
JWH-015, JWH-387, JWH-398, JWH-251, JWH-307, JWH-081, JWH-203, JWH-020, JWH-412,  
AM-694, AM-1220, AM-2233, AM-2201, MAM-2201, methanandamide, RCS-4, RCS-8, RCS-4 
ortho isomer, WIN48, 098, WIN55 212-2   
Protein 
precipitation  
LC-MS/MS-ESI+ 0.015 - 0.9 ; 0.15 - 3 [65] 
(30 SCs): JWH-018, JWH-018 adamantyl derivative,  JWH-073, JWH-250, JWH-081, JWH-122, 
JWH-007, JWH-015, JWH-387, JWH-398, JWH-251, JWH-307, JWH-210, JWH-200, JWH-203, 
JWH-019, JWH-020, AM-2201, AM-2233, AM-694, AM-1220, CRA-13, AB-001, MAM-2201, 
methanandamide, RCS-8, RCS-4, RCS-4 ortho isomer, WIN48 098, WIN55 212-2 
LLE LC-MS/MS-ESI+ 
 
0.015 - 0.9 ; 0.15 - 30 [84] 
(18 SCs): JWH-018, JWH-073, JWH-250, JWH-122, JWH-019, JWH-200, JWH-015, JWH-020, 
JWH-210, JWH-081, JWH-251, HU-210, AM-2201, AM-694, RCS- 4, RCS-4-C4, RCS-8, WIN55 
212-2 
LLE LC-MS/MS-ESI+ LOD = 0.05 - 1.2 [85] 
(UR-144 and 2 metabolites): UR-144 4-OH-pentyl, pyrolysis product of UR-144 
(XLR-11 and 2 metabolites): XLR-11 4-OHpentyl and pyrolysis product of XLR-11 
SPE LC-MS/MS-ESI+ 0.35 - 1.93 ; 5 [45] 
(6 SCs): JWH-018, JWH-073, JWH-250, HU-210, CP47,497, CP47,497 (C8) SPE LC-MS/MS-ESI+/- LOQ = 0.5  [97] 
(7 SCs): JWH-018, JWH-073, JWH-250, JWH-200, HU-211, CP47,497, CP47,497 (C8)     SPE LC-MS/MS-ESI+/- 0.025 - 1.0 ; 0.1 - 2.5 [98] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Bioanalytical procedures for determination of SCs and metabolites in hair samples. 
SCs Sample preparation Detection mode LOD (pg/mg); LOQ (pg/mg) References 
(18 SCs): JWH-018, JWH-073, JWH-018-N-NCOOH, JWH-250, JWH-200, JWH-122, JWH-210, 
JWH-081, JWH-015, JWH-020, JWH-019, JWH-203, JWH-007, HU-210, CP47,497, AM-2201, AM-
694,WIN55 212-2  
Washing, Digestion LC-MS/MS-ESI+ LOQ = 500 [136] 
(JWH-018 and 3 metabolites): JWH-018 N-4- and 5-OH-pentyl, N-NCOOH 
(JWH-073 and 3 metabolites): JWH-073 N-3- and -4-OHbutyl, N-COOH 
Washing, LLE LC-MS/MS-ESI+ LOD = 0.05 [86] 
(5 SC and 11 metabolites):  JWH-018, JWH-073, JWH-122, AM2201, MAM2201, JWH-018 N-4- 
and 5-OH-pentyl, N-NCOOH, JWH-073 N-3- and -4-OHbutyl, N-COOH, JWH-122 N-5-OH-pentyl, 
N-COOH, AM-2201 N-4-OH-pentyl, 6-OH-indole, MAM-2201 N-4-OHpentyl 
Washing, LLE LC-MS/MS-ESI+ 0.05 ; 0.1 [87] 
(23 SCs): JWH-018, JWH-073, JWH-250, JWH-122, JWH-019, JWH-200, JWH-015, JWH-020, 
JWH-210, JWH-081, JWH-251, JWH-307, JWH-007, JWH-398, JWH-203, HU-210, AM-694, AM-
2201, AM-1220, RCS- 4, RCS-8, WIN55 212-2, WIN48 098 
Washing, Digestion, 
LLE 
LC-MS/MS-ESI+ 0.2 – 1.3 ; 0.7 – 4.3 except 
(HU-210 = 80 LOQ)   
[88] 
(8 SCs): JWH-018, JWH-073, JWH-250, JWH-200, JWH-122, JWH-210, JWH-081, AM-694  Base hydrolysis, LLE LC-TOF-MS-ESI+ LOD = 10 [89] 
(5 SCs): JWH-018, JWH-073, JWH-250, JWH-200, HU-210 Washing, digestion, 
LLE 
LC-MS/MS-ESI+ 0.02 – 0.18 ; 0.07 - 18 [90] 
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